Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1
By
- AMS
posted
Jul 14, 2020 06:53 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study
- AMS
Added Apr 16, 2020
Blog Entry
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
- AMS
Added Aug 05, 2021
Blog Entry
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis
- AMS
Added Mar 18, 2021
Blog Entry
Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience
- AMS
Added Aug 05, 2020
Blog Entry
Merz Aesthetics Announces Positive Results From Study Demonstrating Efficacy and Safety of Belotero Balance
The Aesthetic GUIDE
Added Jun 14, 2023
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic